Evidence map›Paper›PMID 32326494›Full record

ReviewAntioxidants (Basel, Switzerland)2020

Oxidative Stress, a Crossroad Between Rare Diseases and Neurodegeneration.

Carmen Espinós, Máximo Ibo Galindo, María Adelaida García-Gimeno, José Santiago Ibáñez-Cabellos, Dolores Martínez-Rubio, José María Millán, Regina Rodrigo, Pascual Sanz, Marta Seco-Cervera, Teresa Sevilla and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 63 citations in OpenAlex.

  1. IBRO neuroscience reports · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Neuroprotective Effects ofNeurochemical research · 2024
    Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Mitochondrial Factors in the Cell Nucleus.International journal of molecular sciences · 2023
    Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Carmen EspinósUnit of Genetics and Genomics of Neuromuscular and Neurodegenerative Disorders, Centro de Investigación Príncipe Felipe (CIPF), 46012 Valencia, Spain.
Máximo Ibo GalindoInstituto Interuniversitario de Investigación de Reconocimiento Molecular y Desarrollo Tecnológico (IDM), Universitat Politècnica de València, Universitat de València, 46022 Valencia Spain.
María Adelaida García-GimenoDepartment of Biotechnology, Escuela Técnica Superior de Ingeniería Agronómica y del Medio Natural (ETSIAMN), Universitat Politècnica de València, 46022 Valencia, Spain.
José Santiago Ibáñez-CabellosRare Diseases Joint Unit, CIPF-INCLIVA, 46010 Valencia, Spain.
Dolores Martínez-RubioUnit of Genetics and Genomics of Neuromuscular and Neurodegenerative Disorders, Centro de Investigación Príncipe Felipe (CIPF), 46012 Valencia, Spain.
José María MillánRare Diseases Joint Unit, CIPF-IIS La Fe, 46026 Valencia, Spain.
Regina RodrigoRare Diseases Joint Unit, CIPF-IIS La Fe, 46026 Valencia, Spain.
Pascual SanzInstituto de Biomedicina de Valencia (IBV)-CSIC Associated Unit, Centro de Investigación Príncipe Felipe (CIPF), 46010 Valencia, Spain.
Marta Seco-CerveraRare Diseases Joint Unit, CIPF-INCLIVA, 46010 Valencia, Spain.
Teresa SevillaRare Diseases Joint Unit, CIPF-IIS La Fe, 46026 Valencia, Spain.
Andrea TapiaLaboratory of Developmental Biology and Disease Models, UPV-CIPF Joint Research Unit Disease Mechanisms and Nanomedicine, Centro de Investigación Príncipe Felipe, 46012 Valencia, Spain.
Federico V PallardóRare Diseases Joint Unit, CIPF-INCLIVA, 46010 Valencia, Spain.
Instituto de Salud Carlos III · ESUniversitat de València · ESCentro de Investigacion Principe Felipe · ESINCLIVA Health Research Institute · ESInstituto de Biomedicina de Valencia · ESUniversitat Politècnica de València · ES

Funding

Suppressing glycogen storage with small molecule inhibitors as a therapeutic approach to Lafora DiseaseP01NS097197 · NINDS · UNIVERSITY OF KENTUCKY · PI GAO, TIANYAN · 2016 to 2021
$9.0M
Generalitat Valenciana PROMETEO/2018/135NINDS NIH HHS P01 NS097197
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Charcot-Marie-Tooth disease (CMT)Dravet syndromeFriedreich’s ataxiainherited retinal dystrophy (IRD)Lafora disease (LD)neurodegenerative disorders with brain iron accumulation (NBIA)progressive myoclonus epilepsy (PME)Unverricht–Lundborg disease (ULD)

Identifiers

PMID32326494
PMCPMC7222183
OpenAlexW3016667348

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.